Tecartus (brexucabtagene autoleucel)
pCPA File Number: 21582
Under consideration for negotiation
For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi)
Gilead Sciences Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: